Solabegron Pulsatile Release for Receptor Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prolonged administration of beta-3 adrenoceptor agonists, such as solabegron, can lead to receptor desensitization, reducing the therapeutic response over time as the receptors become less responsive due to prolonged exposure, necessitating higher doses to achieve the same effect.
Innovation Solution
A pharmaceutical composition that achieves a first and second target plasma concentration of solabegron through a pulsatile release profile, minimizing receptor desensitization by allowing recovery time between releases, thereby maintaining therapeutic efficacy with reduced dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If solabegron is administered continuously at high plasma concentrations, then therapeutic response is maintained, but receptor desensitization occurs reducing efficacy over time
Solution Approach 1:
The patent applies periodic action by implementing a pulsatile release profile that alternates between high plasma concentration phases (when solabegron is released) and low plasma concentration phases (when release is minimized). This periodic fluctuation allows the beta-3 adrenoceptor to recover during low concentration periods while maintaining therapeutic effect during high concentration periods, thereby preventing continuous desensitization that would occur with sustained high concentration administration.
2Reliability
If immediate release formulation is administered twice daily, then therapeutic effect is achieved, but receptor desensitization increases compared to modified release
Solution Approach 1:
The modified release formulation creates a more favorable periodic pattern compared to twice-daily immediate release by extending the low concentration phase duration. The pulsatile release maintains therapeutic effect through periodic high concentration bursts while providing longer recovery intervals, reducing the cumulative desensitization effect that occurs with more frequent immediate release dosing.
Solution Approach 2:
The patent employs dynamics by creating a time-varying plasma concentration profile with distinct high and low phases, rather than maintaining a static high concentration level. This dynamic approach allows the system to adapt between therapeutic activation and receptor recovery states, optimizing both efficacy and preventing desensitization.
3Duration of action of moving object
If prolonged exposure to solabegron occurs, then continuous therapeutic coverage is maintained, but receptor down-regulation decreases the number of receptor molecules
Solution Approach 1:
The pulsatile release profile implements periodic action by cycling between therapeutic activation phases (high concentration providing continuous coverage) and recovery phases (low concentration allowing receptor molecule replenishment). This periodic pattern maintains overall therapeutic coverage while periodically restoring receptor availability, preventing the progressive down-regulation that would occur with uninterrupted prolonged exposure.
Data Source
AI summary
This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.